AUPH Aurinia Pharmaceuticals Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1600620 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.0%
TTM net income YoY303.7%
TTM EPS YoY308.9%
Revenue 3-yr CAGR26.5%
Net income 3-yr CAGR—
Margins
Gross margin90.6%
Operating margin48.6%
Net margin97.7%
FCF margin—
EBITDA margin54.6%
Returns
ROE61.4%
ROA46.4%
ROIC (approx.)34.6%
Asset turnover0.48x
Leverage & solvency
Liabilities / assets20.4%
Debt / equity0.00x
Current ratio6.12x
Interest coverage40.36x
Cash quality & payout
Operating cash flow / net income0.56x
Accruals ratio20.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $83.70M | $83.22M | $77.70M | $77.11M | $73.47M | $70.01M | $62.47M | $59.87M |
| Cost of revenue | $8.31M | $6.55M | $6.50M | $8.80M | $8.18M | $7.12M | $8.57M | $5.55M |
| Gross profit | $75.39M | $76.67M | $71.20M | $68.31M | $65.29M | $62.89M | $53.89M | $54.31M |
| R&D expense | $16.61M | $13.05M | $7.47M | $10.89M | $8.44M | $7.43M | $5.74M | $8.11M |
| SG&A expense | $24.68M | $23.51M | $22.03M | $29.25M | $26.18M | $26.02M | $20.34M | $37.03M |
| Operating income | $35.36M | $46.34M | $41.42M | $33.24M | $29.75M | $20.08M | $21.85M | -$1.67M |
| Interest expense | $867,000 | $948,000 | $1.01M | $1.05M | $1.10M | $1.12M | $1.07M | $1.15M |
| Pretax income | $38.72M | $48.79M | $43.92M | $35.69M | $31.96M | $22.16M | $24.35M | $1.17M |
| Income tax | $7.01M | $11.37M | $9.57M | -$175.10M | $411,000 | $643,000 | $1.00M | -$256,000 |
| Net income | $31.70M | $37.41M | $34.35M | $210.79M | $31.55M | $21.51M | $23.34M | $1.43M |
| EBITDA | $40.20M | $51.17M | $46.24M | $38.10M | $34.61M | $24.95M | $26.70M | $3.19M |
| EPS (basic) | 0.24 | 0.29 | 0.26 | 1.60 | 0.24 | 0.16 | 0.17 | 0.01 |
| EPS (diluted) | 0.23 | 0.28 | 0.25 | 1.53 | 0.23 | 0.16 | 0.16 | 0.01 |
| Weighted avg. shares (diluted) | 135.17M | 133.53M | 137.64M | — | 136.01M | 137.53M | 143.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $45.79M | $179.73M | $40.75M | $80.21M | $72.89M | $52.91M | $66.11M | $83.43M |
| Inventory | $43.73M | $45.15M | $46.41M | $45.69M | $44.79M | $46.50M | $46.20M | $39.23M |
| Current assets | $587.89M | $541.32M | $480.24M | $491.97M | $438.74M | $408.97M | $405.76M | $446.60M |
| PP&E, net | $1.74M | $1.86M | $1.99M | $2.11M | $2.27M | $2.42M | $2.58M | $2.73M |
| Intangibles | $3.17M | $3.38M | $3.59M | $3.76M | $3.90M | $4.05M | $4.16M | $4.36M |
| Total assets | $825.70M | $792.26M | $724.00M | $751.59M | $527.53M | $502.56M | $504.85M | $550.64M |
| Current liabilities | $96.00M | $99.89M | $86.56M | $93.72M | $76.22M | $78.27M | $68.41M | $97.76M |
| Total liabilities | $168.19M | $177.40M | $156.37M | $170.26M | $161.76M | $167.26M | $154.66M | $173.17M |
| Shareholders' equity | $657.52M | $614.86M | $567.63M | $581.33M | $365.77M | $335.30M | $350.19M | $377.48M |
| Shares outstanding | 134.00M | 132.91M | 130.77M | 132.32M | 131.84M | 132.67M | 137.75M | 140.88M |
| Cash flow statement | ||||||||
| Operating cash flow | $46.37M | $52.57M | $32.56M | $45.67M | $44.45M | $44.24M | $1.30M | $30.11M |
| Investing cash flow | -$175.73M | $81.45M | -$18.08M | -$36.76M | -$13.77M | -$13.27M | $31.03M | $39.22M |
| Financing cash flow | -$4.32M | $4.81M | -$53.69M | -$1.89M | -$10.49M | -$44.39M | -$49.34M | -$23.05M |
| Depreciation & amortization | $4.84M | $4.83M | $4.82M | $4.86M | $4.87M | $4.86M | $4.86M | $4.86M |
| Stock-based compensation | $6.12M | $2.84M | -$866,000 | $6.73M | $5.92M | $5.44M | -$3.41M | $8.95M |
| Share buybacks | $0 | $38.72M | $36.16M | $0 | $8.67M | $42.56M | $46.92M | $21.80M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.